Cargando…

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies

Detalles Bibliográficos
Autores principales:	Sahasrabudhe, Siddhee A., Al-Kofahi, Mahmoud, Cloyd, James C., Weinreb, Neal, Kartha, Reena V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849568/ http://dx.doi.org/10.1016/j.ymgme.2020.12.225

Ejemplares similares

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2023)

Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
por: Mistry, Pramod, et al.
Publicado: (2020)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

COVID-19 patient impact: A survey of the Gaucher community involving patients, caregivers and family members based in the US to determine impact of the pandemic
por: Ryan, Emory, et al.
Publicado: (2021)

Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
por: Orenstein, Marissa, et al.
Publicado: (2014)

A new framework for evaluating the health impacts of treatment for Gaucher disease type 1
por: Ganz, Michael L., et al.
Publicado: (2017)

N-Acetylcysteine Reverses the Mitochondrial Dysfunction Induced by Very Long-Chain Fatty Acids in Murine Oligodendrocyte Model of Adrenoleukodystrophy
por: Zhou, Jie, et al.
Publicado: (2021)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2012)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
por: Weinreb, Neal J., et al.
Publicado: (2013)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Pathological looping in the synucleinopathies: investigating the link between Parkinson’s disease and Gaucher disease
por: Kinghorn, Kerri J.
Publicado: (2011)

Mutational Analysis and Genotype Investigation of Less Known Gaucher Mutations through Haplotype Analysis in Iranian Gaucher Patients
por: Sardarpour, Negar, et al.
Publicado: (2023)

Use of Ambroxol as Therapy for Gaucher Disease
por: Zhan, Xia, et al.
Publicado: (2023)

Gaucher: A Systematic Review on Oral and Radiological Aspects
por: Minervini, Giuseppe, et al.
Publicado: (2023)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Association Between Progranulin and Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
por: Okour, Malek, et al.
Publicado: (2020)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)
por: Weinreb, Neal J., et al.
Publicado: (2015)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

N-acetylcysteine Provides Cytoprotection in Murine Oligodendrocytes through Heme Oxygenase-1 Activity
por: Zhou, Jie, et al.
Publicado: (2020)

In-depth phenotyping for clinical stratification of Gaucher disease
por: D’Amore, Simona, et al.
Publicado: (2021)

Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

Eye movement biomarkers allow for the definition of phenotypes in Gaucher Disease
por: Donald, Aimee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gd950dda4pafi2sn77c52ksbj8